English
  • English
  • French
Dayvigo

Welcome to

dayvigo
{{form.license.errorMessage}} Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon {{form.province.errorMessage}} I certify that I am a Healthcare professional. {{form.isAgreeToTermsSignUp.errorMessage}}

As you explore DAYVIGO.ca be sure to take a look at the tools and resources we’ve provided to help you and your patients.

This information is intended for Canadian health care professionals only. Click the "CONTINUE" button below to verify that you are a Canadian health care professional.

loading Continue

Sorry! 

Something went wrong during the processing of your request. Please come back later and try again.
  • Privacy Policy
  • Legal Notice and Disclaimers
  • Site Map

This site is intended for Canadian Healthcare Professionals only.

DAYVIGO® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

Eisai Logo

© 2023 Eisai Ltd. All rights reserved.

www.eisai.ca

INDICATION AND CLINICAL USE

Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder.
Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the patient has been carefully evaluated.

DAYVIGO™ (lemborexant) is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

DAYVIGO is not recommended for patients under the age of 18 years.

DAYVIGO is not recommended in patients with severe hepatic impairment.

CONTRAINDICATIONS

• Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

• Patients with narcolepsy.

RELEVANT WARNINGS AND PRECAUTIONS

• Abnormal thinking and behavioural changes

• CNS depressant effects (including alcohol) and daytime impairment and risk of falls

• Complex sleep behaviours

• Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms

• Worsening of depression/suicidal ideation

• Co-morbid diagnoses

• Drug interactions – inhibitors and inducers of CYP3A

• Patients with galactose intolerance

• Driving and operating machinery

• Patients with dependence/tolerance and abuse liability

• Rebound insomnia

• Patients with hepatic impairment

• Patients with compromised respiratory function

• Pregnant or breastfeeding women

FOR MORE INFORMATION

Please see the Product Monograph at https://ca.eisai.com/en-CA/our-products for important information on adverse reactions, drug interactions, and dosing not discussed in this piece. The Product Monograph is also available by calling 1-877-873-4724.

Continue